Orisomes Biotech

Orisomes Biotech (Qingdao) Co., Ltd. is a biotechnology company specializing in anti-aging and rejuvenation research and development. The core achievement of Orisomes Biotech, the small nucleic acid OS110, enables senescent cells to "rejuvenate" by precisely targeting the core hub of cell cycle arrest (Cdkn1a/Ccng2), restoring their proliferation and tissue repair functions, thereby achieving an "anti-aging" effect from the cellular to the organismal level. The company has established a "one-body-two-wing" product portfolio: the "body" is the anti-aging technology platform centered on OS110, while the "two wings" are the serious medical pipeline and consumer medical pipeline extended from this platform. The company’s consumer medical products realize the direct application of OS110 in the field of skin anti-aging. Its skincare series has completed registration for four products and plans to expand to 13, covering facial cleansers, serums, creams, and masks. Products are divided into high-end lines (for groups with existing wrinkles) and mid-range lines (for groups focused on aging prevention) based on OS110 concentration levels.